Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20843153 | 0.90 | KDM1A (0.53) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL17987974 | 0.89 | KDM1A (0.52) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL20843229 | 0.89 | KDM1A (0.52) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL27970622 | 0.88 | DRD2 (0.47) | DRD2DRD4KDM4EHRH3CHRM4 | |
| SCHEMBL19764432 | 0.86 | KDM1A (0.51) | KDM1ADRD2DRD4KDM4EHRH3 | |
| SCHEMBL20843175 | 0.86 | KDM1A (0.58) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL28175300 | 0.86 | KDM4E (0.50) | KDM1ADRD2DRD4KDM4EHRH3 | |
| SCHEMBL15033023 | 0.86 | KDM4E (0.50) | KDM1ADRD2DRD4KDM4EHRH3 | |
| SCHEMBL17988090 | 0.85 | KDM4E (0.65) | KDM1AKDM4ECHRM4 | |
| SCHEMBL17963554 | 0.85 | KDM4E (0.55) | KDM1ADRD2DRD4KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM3B | KDM1A 2/4885DRD2 3467/4885DRD4 3828/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885DRD2 3467/4885DRD4 3828/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885DRD2 3467/4885DRD4 3828/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885DRD2 3467/4885DRD4 3828/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885DRD2 3467/4885DRD4 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.